Allylescaline

The official German schedule identifies the compound by its chemical name rather than the English trivial name.

MHLW's current designated-substances schedule identifies the exact Allylescaline chemical name and its salts as a designated substance; the designation notice gives an effective date of 4 April 2015. Allylescaline is not listed in the current narcotics schedules (Narcotics and Psychotropics Control Act Appendix 1 or Cabinet Order Article 1) or either psychotropics schedule. Under PMD Act Article 76-4, a designated substance may not be manufactured, imported, sold, transferred, possessed, purchased, received, or used for any purpose other than the Act's medical等用途 (medical diagnosis, treatment or prevention, and specified non-harmful uses). Accordingly, ordinary non-medical possession, use, supply, and import are prohibited; this is not a prescription-only classification. For a non-business violation, Article 84(28) provides up to three years' 拘禁刑 (拘禁刑; custodial sentence) or a fine up to ¥3,000,000, or both. Business manufacture, import, sale, transfer, or possession for sale/transfer (storage or display for that purpose) is separately covered by Article 83-9 and carries up to five years' 拘禁刑 or a fine up to ¥5,000,000, or both. These are statutory maximums.

Classified as an illegal substance since January 2016.¹³

Production, supply, and import prohibited under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016.²²

DEA's lists are not comprehensive, and the federal analogue test depends on case-specific facts. Allylescaline is not directly named in the federal schedules; an unlisted substance may nevertheless be treated as a scheduled substance or regulated as a controlled-substance analogue. Allylescaline and mescaline share a substituted phenethylamine framework: allylescaline is 2-(3,5-dimethoxy-4-prop-2-enoxyphenyl)ethanamine, whereas mescaline is 2-(3,4,5-trimethoxyphenyl)ethanamine. This structural similarity may implicate 21 U.S.C. § 802(32), but whether allylescaline satisfies the statutory substantial-similarity/effect or representation test in a particular prosecution remains unresolved. If treated as an analogue to the extent intended for human consumption, § 813 treats it as Schedule I for federal-law purposes. Section 841(a) prohibits knowing or intentional manufacture, distribution, dispensing or possession with intent to do so; § 841(b)(1)(C) supplies the Schedule I/II penalty ceiling of up to 20 years (up to 30 years after a prior felony drug conviction, with enhanced consequences where death or serious bodily injury results). Simple possession under § 844(a) carries up to 1 year and a minimum $1,000 fine for a first offense, with higher repeat-offense ranges; § 846 applies the same penalties to attempts and conspiracies. These are statutory ranges; application of the federal analogue provisions remains case-specific.

The binding current consolidated BetmVV-EDI expressly names Allylescalin at item 148 in Annex 6. NIH PubChem identifies Allylescaline (CID 44719469, CAS 39201-75-7) as 2-(3,5-dimethoxy-4-prop-2-enoxyphenyl)ethanamine, the same connectivity as the Swiss designation; Swissmedic's supplementary list supplies the freebase and hydrochloride CAS numbers and repeats the Swiss chemical designation. BetmVV-EDI Article 1(2) covers substances listed in Annexes 1–6 and specified salts, esters, ethers, carbamates, stereoisomers and preparations containing them, so the named freebase and covered salt forms are scheduled. BetmKV Article 3(2)(e) subjects Verzeichnis-e substances to Verzeichnis-a control measures, Article 5(2) assigns their operating permit to the EDI, and Article 11(1) requires an operating permit for handling activities including manufacture, obtaining, brokering, import/export, supply and trade. BetmG Article 7(1) requires EDI authorization and compliance with its conditions for cultivating, manufacturing, importing/exporting, storing, using or placing Article 7 materials/products into circulation; Article 20(1)(c) provides up to three years' imprisonment or a monetary penalty for specified unauthorized handling. The Verzeichnis-e listing subjects allylescaline to controlled or restricted treatment, not a categorical Verzeichnis-d prohibition or an ordinary prescription or consumer route. Swissmedic's ancillary lists are not exhaustive; only the BetmVV-EDI schedules are binding.